Delta Plane Crashes at Pearson, All Passengers Survive
A Delta Air Lines regional jet crashed upon landing Monday afternoon at Toronto Pearson International Airport and flipped over. All 80 people on board survived, officials said.The 76 passengers and four crew members were evacuated from the plane, a CRJ-900 regional jet, after the accident, which occurred around 2:15 p.m. ET, Delta said. Two people were airlifted in critical condition, according to Peel Regional Paramedic Services. Delta said Tuesday morning that 19 of 21 passengers who were taken to local hospitals had been released.Video on social media appeared to show the aircraft hitting the runway, before fire and smoke emerged and the airplane flipped over.Delta Flight 4819, operated by the carrier’s regional subsidiary Endeavor Air, originated in Delta’s hub of Minneapolis–Saint Paul International Airport.Flights to the Toronto airport were temporarily halted but resumed as of 5 p.m. ET on Monday. Delta canceled the rest of its flights to and from Toronto on Monday and issued travel waivers to affected passengers.“Our most pressing priority remains taking care of all customers and Endeavor crew members who were involved,” Delta CEO Ed Bastian said in a statement. “We are grateful for all the first responders and medical teams who have been caring for them.”DAL shares lost 21 cents to $65.18.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


